Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cencora, Inc. - SIC # 7690 -
Ticker
Exchange
SIC #
Website
Latest Ticker
COR
New York
7690
www.cencora.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cencora, Inc.
Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII
- Jun 8th, 2026 11:12 am
Is Cencora Stock Underperforming the Nasdaq?
- Jun 8th, 2026 7:55 am
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
- Jun 5th, 2026 9:30 am
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know
- Jun 5th, 2026 7:55 am
Is McKesson Stock Underperforming the Dow?
- Jun 3rd, 2026 5:05 am
Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies
- Jun 2nd, 2026 6:00 am
Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)?
- Jun 1st, 2026 5:11 pm
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
- Jun 1st, 2026 12:39 pm
LUCENT Appoints Simon Doyle as CEO with Matthew Goodman Taking Chief Medical Officer Position
- Jun 1st, 2026 1:00 am
Cencora nabs ex-CVS exec as new CFO
- May 27th, 2026 5:14 am
Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
- May 27th, 2026 4:55 am
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
- May 21st, 2026 2:30 pm
3 Market-Beating Stocks to Research Further
- May 18th, 2026 11:32 pm
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating
- May 18th, 2026 6:36 am
Cencora Legal Probes Test Investor Confidence After Weaker Q2 Revenue Outlook
- May 17th, 2026 3:13 pm
The Top 5 Analyst Questions From Cencora’s Q1 Earnings Call
- May 16th, 2026 3:56 pm
Wells Fargo Maintains Overweight Rating on Cencora (COR)
- May 15th, 2026 7:25 am
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?
- May 14th, 2026 11:06 am
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
- May 13th, 2026 8:40 am
Cencora Q2 Earnings Call Highlights
- May 9th, 2026 3:04 pm
Scroll